Sequenom Settles Ibis Dispute
Luke Timmerman10/27/09
Sequenom, the San Diego-based maker of laboratory tools and diagnostics, said today in a regulatory filing it has agreed to accept a $1 million payment from Ibis Biosciences, a unit of Abbott Laboratories, to settle a patent infringement lawsuit. As part of the deal, Sequenom (NASDAQ: SQNM) has granted Ibis a non-exclusive license to three mass spectrometry-based patents. Abbott acquired Ibis, a spinoff from Carlsbad, CA-based Isis Pharmaceuticals, for $215 million in December.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
